[HTML][HTML] Cancer vaccines: the next immunotherapy frontier
MJ Lin, J Svensson-Arvelund, GS Lubitz, A Marabelle… - Nature cancer, 2022 - nature.com
After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …
Therapeutic cancer vaccines
M Saxena, SH van der Burg, CJM Melief… - Nature Reviews …, 2021 - nature.com
Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …
understanding of the breadth of tumour-associated antigens, the native immune response …
[HTML][HTML] Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy
RL Barrett, E Puré - Elife, 2020 - elifesciences.org
Fibroblasts play an essential role in organogenesis and the integrity of tissue architecture
and function. Growth in most solid tumors is dependent upon remodeling 'stroma', composed …
and function. Growth in most solid tumors is dependent upon remodeling 'stroma', composed …
CD4+ T cell help in cancer immunology and immunotherapy
Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within
a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish …
a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish …
[HTML][HTML] Exosome-based vaccines: history, current state, and clinical trials
P Santos, F Almeida - Frontiers in immunology, 2021 - frontiersin.org
Extracellular vesicles (EVs) are released by most cell types as part of an intracellular
communication system in crucial processes such as inflammation, cell proliferation, and …
communication system in crucial processes such as inflammation, cell proliferation, and …
Bioinspired and biomimetic delivery platforms for cancer vaccines
Cancer vaccines aim at eliciting tumor‐specific responses for the immune system to identify
and eradicate malignant tumor cells while sparing the normal tissues. Furthermore, cancer …
and eradicate malignant tumor cells while sparing the normal tissues. Furthermore, cancer …
[HTML][HTML] Towards personalized, tumour-specific, therapeutic vaccines for cancer
Z Hu, PA Ott, CJ Wu - Nature Reviews Immunology, 2018 - nature.com
Cancer vaccines, which are designed to amplify tumour-specific T cell responses through
active immunization, have long been envisioned as a key tool of effective cancer …
active immunization, have long been envisioned as a key tool of effective cancer …
Elements of cancer immunity and the cancer–immune set point
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But
despite the clinical success of antibodies against the immune regulators CTLA4 and PD …
despite the clinical success of antibodies against the immune regulators CTLA4 and PD …
Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions
M Ralli, A Botticelli, IC Visconti… - Journal of …, 2020 - Wiley Online Library
Melanoma is one of the most immunologic malignancies based on its higher prevalence in
immune‐compromised patients, the evidence of brisk lymphocytic infiltrates in both primary …
immune‐compromised patients, the evidence of brisk lymphocytic infiltrates in both primary …
[HTML][HTML] Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint
J Wischhusen, I Melero, WH Fridman - Frontiers in Immunology, 2020 - frontiersin.org
Growth/differentiation factor-15 (GDF-15), also named macrophage inhibitory cytokine-1, is a
divergent member of the transforming growth factor β superfamily. While physiological …
divergent member of the transforming growth factor β superfamily. While physiological …